EGFR and cancer: Although, recent advancements in therapeutics have made it possible to overcome EGFR-TKIs resistant cancer types, however, the adverse effects, unmapped targets and cellular responses to the available drugs require further investigation (Yuan H. et al., 2016; Chen et al., 2017; Chen et al., 2019).